Latest Commercialisation News

EV Resources has secured a 70% stake in the Los Lirios Antimony Project, unveiling high-grade mineralisation and plans for a pilot plant to accelerate production. Leadership enhancements and portfolio rationalisation underscore its strategic pivot to critical minerals.

Galan Lithium has locked in a $20 million strategic placement and secured a key Argentine government incentive, positioning its Hombre Muerto West project for production in early 2026.

Strategic Elements Ltd has marked significant progress in its Energy Ink™ prototype trials and underground mining technology, maintaining a robust financial footing with $4.21 million cash and no debt.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

First Graphene Limited reports over A$1.2 million in annual income, driven by new commercial orders and breakthrough graphene applications in mining safety boots and cement additives.

Bio-Gene Technology Limited has secured $2.45 million to fund critical safety studies and scale-up production of its novel insecticides Flavocide and Qcide, positioning the company for upcoming regulatory approvals and commercial partnerships.

Firebird Metals has made significant strides in its lithium manganese iron phosphate (LMFP) battery strategy, unveiling a new lab-scale cathode production facility and securing key patents. The company also demonstrated major energy savings in kiln trials, positioning itself strongly in the evolving battery materials market.

Zelira Therapeutics reports promising diabetic neuropathy study results with ZLT-L-007 surpassing Lyrica, while converting $3.25 million in notes to equity to bolster HOPE® 1 clinical development.

Aeris Environmental reported a robust 62% revenue increase in the June 2025 quarter, driven by new international contracts and expanding adoption of its Syncromesh IoT platform.

Orbital Corporation reports a $0.5 million operating cash outflow for Q2 2025, while progressing development of a larger UAV engine now entering customer flight trials.

Cambium Bio has raised A$2.12 million through a fully subscribed placement led by Taiwanese institutional investor Da Jyun Capital, supporting the initiation of pivotal Phase 3 trials for its lead ophthalmology candidate.

Memphasys Limited has submitted its Felix™ sperm separation system for CE Mark approval, targeting Europe’s $5 billion IVF market, while expanding direct sales in Japan and validating its RoXsta™ oxidative stress diagnostic platform.